Interest & Impact of Skin Cancer Genetic Testing

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this study is to learn whether the patient might be interested in skin cancer genetic testing, and if so, what kinds of thoughts, feelings, and behaviors might result from this testing. Testing for skin cancer risk based on the MC1R gene is not currently used in clinical practice; it will be offered in this study for research purposes only.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01662713` - Optical Frequency Domain Imaging for Non-melanoma Skin Cancers	N/A

NCT number	NCT02941900
Study type	Observational
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase
Start date	August 2016
Completion date	January 18, 2023

Interest and Impact of Skin Cancer Genetic Testing

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms